Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

被引：423

作者：

Ghofrani, Hossein A.

Osterloh, Ian H.

Grimminger, Friedrich

机构：

[1] Univ Hosp Giessen & Marburg GmbH, Dept Internal Med, Med Clin 2 5, D-35392 Giessen, Germany

[2] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 08期

关键词：

D O I：

10.1038/nrd2030

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction ( Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.

引用

收藏

页码：689 / 702

页数：14

相关论文

共 201 条

[11] Sildenafil ameliorates effects of inhaled nitric oxide withdrawal [J].

Atz, AM ;

Wessel, DL .

ANESTHESIOLOGY, 1999, 91 (01) :307-310

[12] ENDOTHELIUM-DERIVED NITRIC-OXIDE AND CYCLOOXYGENASE PRODUCTS MODULATE CORPUS CAVERNOSUM SMOOTH-MUSCLE TONE [J].

AZADZOI, KM ;

KIM, N ;

BROWN, ML ;

GOLDSTEIN, I ;

COHEN, RA ;

DETEJADA, IS .

JOURNAL OF UROLOGY, 1992, 147 (01) :220-225

[13] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[14] Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes [J].

Ballard, SA ;

Gingell, CJ ;

Tang, K ;

Turner, LA ;

Price, ME ;

Naylor, AM .

JOURNAL OF UROLOGY, 1998, 159 (06) :2164-2171

[15] Pulmonary hypertension in chronic obstructive pulmonary disease [J].

Barberà, JA ;

Peinado, VI ;

Santos, S .

EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) :892-905

[16] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[17] CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].

BEAVO, JA .

PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748

[18] Pharmacotherapy of Raynaud's phenomenon [J].

Belch, JJF ;

Ho, M .

DRUGS, 1996, 52 (05) :682-695

[19] Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum [J].

Bloch, W ;

Klotz, T ;

Sedlaczek, P ;

Zumbe, J ;

Engelmann, U ;

Addicks, K .

UROLOGICAL RESEARCH, 1998, 26 (02) :129-135

[20] State-dependent impairment in object recognition after hippocampal NOS inhibition [J].

Blokland, A ;

Prickaerts, J ;

Honig, W ;

de Vente, J .

NEUROREPORT, 1998, 9 (18) :4205-4208

← 1 2 3 4 5 6 7 8 9 10 →